The University of Chicago Header Logo

Connection

Sunil Narula to Neoplasm, Residual

Back to Details
This is a "connection" page, showing publications Sunil Narula has written about Neoplasm, Residual.
Sunil Narula
Connection Strength
0.048
Neoplasm, Residual
  1. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.